The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone
- 12 January 2016
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 99 (4), 401-404
- https://doi.org/10.1002/cpt.333
Abstract
The field of pharmacogenomics originally emerged in the 1950s from observations that a few rare individuals had unexpected, severe reactions to drugs. 1 As recently as just 6 years ago, prominent views on the subject had largely remained unchanged, with authors from the US Food and Drug Administration (FDA) citing the purpose of pharmacogenetics as “tailoring treatment for the outliers.” 2 It should not be surprising if this is the prevailing view—the best‐studied pharmacogenomic drug examples are indeed just that, genetic explanations of extreme responses or susceptibilities among usually a very small fraction of the human population. Thiopurine methyltransferase (TPMT) deficiency as a cause of severe myelosuppression upon treatment with azathioprine or mercaptopurine is found as a heterozygous trait in only ∼10% of patients, and homozygous (deficiency) carriers are even more rare—occurring in fewer than 1 in 300 patients. 3, 4 Malignant hyperthermia resulting from inhaled anesthetics and succinylcholine is believed to have a genetic incidence of only about 1 in 2000 people. 5Keywords
This publication has 39 references indexed in Scilit:
- Preemptive Genotyping for Personalized Medicine: Design of the Right Drug, Right Dose, Right Time—Using Genomic Data to Individualize Treatment ProtocolMayo Clinic Proceedings, 2014
- A Randomized Trial of Genotype-Guided Dosing of WarfarinThe New England Journal of Medicine, 2013
- A Pharmacogenetic versus a Clinical Algorithm for Warfarin DosingThe New England Journal of Medicine, 2013
- Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient settingPharmacogenetics and Genomics, 2013
- Economic evaluation of HLA‐B*15:02 screening for carbamazepine‐induced severe adverse drug reactions in ThailandEpilepsia, 2013
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateClinical Pharmacology & Therapeutics, 2013
- The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health Records and Genomics–PharmacogenomicsClinical Pharmacology & Therapeutics, 2013
- Genetic Determinants of Dabigatran Plasma Levels and Their Relation to BleedingCirculation, 2013
- The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World ImplementationClinical Pharmacology & Therapeutics, 2013
- Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost‐effectiveness analysisJournal of Thrombosis and Haemostasis, 2013